微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 37.15% | -6.71% | 5.96% | 98/159 | 48.66% | 恩华药业 | 71.67% | 行业排名> |
| 2026-03-31 | 35.06% | -19.22% | 1.12% | 99/159 | 50.28% | 海创药业 | 97.34% | 行业排名> |
| 2025-12-31 | 34.67% | -18.1% | -7.54% | 107/159 | 50.37% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 37.49% | -6.39% | -5.84% | 97/159 | -2.12% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 39.82% | 12.5% | -8.25% | 93/159 | 15.05% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 43.4% | 31.84% | 2.52% | 86/159 | 31.79% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 42.33% | 30.71% | 5.68% | 97/159 | 51.61% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 40.05% | 19.3% | 13.17% | 99/159 | 22.43% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 35.39% | 4.58% | 7.53% | 107/159 | 32.96% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 32.92% | -2.47% | 1.64% | 110/159 | 51.47% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 32.39% | -6.04% | -3.54% | 115/159 | 51.31% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 33.57% | -6.14% | -0.79% | 109/159 | 32.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 33.84% | -8.84% | 0.27% | 112/159 | 38.22% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 33.75% | -10.72% | -2.08% | 110/159 | 52.66% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 34.47% | -15.62% | -3.64% | 113/159 | 53.51% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 35.77% | -14.04% | -3.65% | 103/159 | 5.67% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 37.13% | -14.03% | -1.79% | 107/159 | 20.91% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 37.8% | -7.8% | -7.46% | 100/159 | 54.06% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 40.85% | -1.66% | -1.83% | 99/159 | 54.9% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 41.61% | -1.14% | -3.64% | 85/159 | 46.49% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 43.18% | 7.84% | 5.32% | 88/159 | 46.97% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 41% | 19.49% | -1.3% | 82/159 | 53.79% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 41.54% | 1.92% | -1.31% | 101/159 | -147.51% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 42.09% | 4.52% | 5.11% | 85/159 | 56.06% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 40.05% | -0.24% | 16.71% | 95/159 | 53.85% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 34.31% | -11.53% | -15.81% | 91/159 | 54.83% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 40.76% | -2.81% | 1.21% | 97/159 | -1232.76% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 40.27% | -8.29% | 0.32% | 76/159 | 54.86% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 40.14% | -18.25% | 3.5% | 79/159 | 54.88% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 38.79% | -33.69% | -7.51% | 76/159 | 50.75% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 41.93% | 41.38% | -4.5% | 88/159 | -210.26% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 43.91% | 77.82% | -10.58% | 64/159 | 53.75% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 49.11% | 107.95% | -16.05% | 55/159 | 53.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 58.49% | 174.58% | 97.21% | 40/159 | 53.78% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 29.66% | 4.56% | 20.11% | 105/159 | 52.25% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 24.69% | -9.98% | 4.57% | 88/159 | 48.76% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 23.61% | -6.3% | 10.85% | 93/159 | 47.61% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 21.3% | 9.78% | -24.9% | 80/159 | 46.62% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 28.37% | 69.38% | 3.41% | 91/159 | 48.17% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 27.43% | 67.01% | 8.84% | 64/159 | 45.83% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 25.2% | 54.97% | 29.88% | 77/159 | 45.93% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 19.41% | 79.62% | 15.87% | 72/159 | 43.86% | 微芯生物 | 97.46% | 行业排名> |